Request Free Sample ×
Glioma Diagnosis and Treatment Market Research Report – Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Glioma Diagnosis Treatment Market

ID: MRFR/Pharma/4421-HCR
100 Pages
Vikita Thakur, Rahul Gotadki
Last Updated: May 15, 2026

Glioma Diagnosis and Treatment Market Research Report Information By Type (Primary Tumors and Secondary Tumors), By Diagnosis (Neurological Exam, CT Scan, MRI, PET Scan, Biopsy, Molecular Testing, EEG, and Others), By Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, and Targeted Therapy), By Grade (Low Grade Glioma, High Grade Glioma, and Recurrent High Grade Glioma), By Location (Supratentorial and Infratentorial), By End User (Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Glioma Diagnosis Treatment Market Infographic
Summary Table of Contents Segmentation Methodology Download PDF

Glioma Diagnosis Treatment Market Summary

As per MRFR analysis, the Glioma Diagnosis Treatment Market Size was estimated at 3576.87 USD Million in 2024. The Glioma Diagnosis Treatment industry is projected to grow from 3762.94 USD Million in 2025 to 6248.39 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.2% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Glioma Diagnosis Treatment Market is experiencing transformative advancements driven by technology and increasing awareness.

  • Advancements in diagnostic technologies, particularly in Magnetic Resonance Imaging, are reshaping the landscape of glioma diagnosis.
  • The emergence of targeted therapies is gaining traction, especially in the Asia-Pacific region, which is the fastest-growing market.
  • There is a growing emphasis on multidisciplinary approaches to treatment, integrating surgery and immunotherapy for enhanced patient outcomes.
  • Key market drivers include the increasing incidence of glioma cases and rising investment in cancer research, particularly in North America.

Market Size & Forecast

2024 Market Size 3576.87 (USD Million)
2035 Market Size 6248.39 (USD Million)
CAGR (2025 - 2035) 5.2%

Major Players

Roche (CH), Novartis (CH), Merck (DE), Bristol-Myers Squibb (US), Eli Lilly (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Glioma Diagnosis Treatment Market Trends

The Glioma Diagnosis Treatment Market is currently experiencing a dynamic evolution, driven by advancements in medical technology and a growing understanding of glioma biology. Innovative diagnostic techniques, such as advanced imaging modalities and molecular profiling, are enhancing the accuracy of glioma detection and characterization. This progress is complemented by the development of targeted therapies and immunotherapies, which are reshaping treatment paradigms. As healthcare systems increasingly prioritize personalized medicine, the Glioma Diagnosis Treatment Market is likely to witness a shift towards more tailored therapeutic approaches, potentially improving patient outcomes and survival rates. Moreover, the rising incidence of gliomas, coupled with an aging population, is propelling demand for effective diagnostic and treatment options. Collaborative efforts among research institutions, pharmaceutical companies, and healthcare providers are fostering an environment conducive to innovation. This collaborative spirit may lead to the emergence of novel treatment modalities and diagnostic tools, further enhancing the Glioma Diagnosis Treatment Market. As stakeholders navigate this complex landscape, the focus on patient-centric care and the integration of cutting-edge technologies will likely play a pivotal role in shaping the future of glioma management.

Advancements in Diagnostic Technologies

The Glioma Diagnosis Treatment Market is witnessing a surge in the adoption of advanced diagnostic technologies. Techniques such as MRI and PET scans are becoming more sophisticated, allowing for earlier and more accurate detection of gliomas. Additionally, molecular diagnostics are gaining traction, enabling personalized treatment plans based on the genetic profile of tumors.

Emergence of Targeted Therapies

Targeted therapies are increasingly becoming a focal point within the Glioma Diagnosis Treatment Market. These treatments aim to specifically attack cancer cells while sparing healthy tissue, potentially leading to improved efficacy and reduced side effects. The development of such therapies is indicative of a broader trend towards precision medicine in oncology.

Growing Emphasis on Multidisciplinary Approaches

There is a notable shift towards multidisciplinary approaches in the management of gliomas. This trend involves collaboration among neurosurgeons, oncologists, radiologists, and other specialists to create comprehensive treatment plans. Such teamwork is believed to enhance patient care and optimize treatment outcomes in the Glioma Diagnosis Treatment Market.

Glioma Diagnosis Treatment Market Drivers

Rising Incidence of Glioma

The increasing prevalence of glioma cases globally appears to be a primary driver for the Global Glioma Diagnosis and Treatment Market Industry. As reported, the incidence rate of gliomas has been on the rise, with estimates suggesting that approximately 3.19 per 100,000 individuals are diagnosed annually. This trend is likely to escalate the demand for advanced diagnostic tools and treatment options, contributing to the market's growth. By 2024, the market is projected to reach 3.58 USD Billion, reflecting the urgent need for effective interventions and comprehensive care strategies for glioma patients.

Advancements in Diagnostic Technologies

Technological innovations in diagnostic methodologies are significantly influencing the Global Glioma Diagnosis and Treatment Market Industry. Enhanced imaging techniques, such as MRI and PET scans, have improved the accuracy of glioma detection, allowing for earlier intervention. Furthermore, the integration of artificial intelligence in imaging analysis is expected to refine diagnostic precision. These advancements not only facilitate timely treatment but also enhance patient outcomes. As the market evolves, the demand for these sophisticated diagnostic tools is likely to contribute to the projected growth, with the market anticipated to reach 6.25 USD Billion by 2035.

Emerging Markets and Global Accessibility

The expansion of healthcare infrastructure in emerging markets is a significant driver for the Global Glioma Diagnosis and Treatment Market Industry. Countries with developing healthcare systems are increasingly investing in oncology services, improving access to glioma diagnosis and treatment. This trend is likely to enhance patient outcomes and increase the number of diagnosed cases, further stimulating market growth. As these regions continue to develop, the market is expected to benefit from the rising demand for glioma-related healthcare services, contributing to the overall market value projected to be 3.58 USD Billion by 2024.

Growing Awareness and Education Initiatives

Raising awareness about glioma and its treatment options is becoming increasingly vital in the Global Glioma Diagnosis and Treatment Market Industry. Educational campaigns aimed at healthcare professionals and the general public are essential for early detection and intervention. These initiatives help demystify glioma, encouraging individuals to seek medical advice promptly. As awareness grows, the demand for diagnostic services and treatment options is likely to increase, contributing to the overall market expansion. This trend aligns with the projected growth trajectory, as the market is expected to reach 6.25 USD Billion by 2035.

Increased Research and Development Investments

The surge in research and development investments in glioma therapies is a crucial factor propelling the Global Glioma Diagnosis and Treatment Market Industry. Governments and private organizations are allocating substantial funds to explore novel treatment modalities, including immunotherapy and targeted therapies. This increased focus on R&D is expected to yield innovative solutions that could improve survival rates and quality of life for glioma patients. As a result, the market is projected to experience a compound annual growth rate of 5.19% from 2025 to 2035, reflecting the potential for groundbreaking advancements in glioma treatment.

Market Segment Insights

By Diagnosis Method: Magnetic Resonance Imaging (Largest) vs. Biopsy (Fastest-Growing)

In the Glioma Diagnosis Treatment Market, Magnetic Resonance Imaging (MRI) represents the largest share among the diagnosis methods due to its non-invasive nature and superior imaging capabilities. With advancements in technology, MRI has gained prominence in accurately characterizing gliomas, making it an essential tool in the diagnosis process. Meanwhile, other methods such as Computed Tomography (CT) and Positron Emission Tomography (PET) play significant roles, but they do not match MRI's widespread acceptance. Biopsy, in contrast, is regarded as the fastest-growing diagnosis method, as it provides definitive histological diagnosis, crucial for effective treatment planning. The growth trends in the Glioma Diagnosis Treatment Market are influenced by several factors, including technological advancements, increased awareness of glioma symptoms among patients, and developments in imaging techniques that enhance diagnostic accuracy. The rising integration of artificial intelligence in diagnostic procedures aids in enhancing precision and speed, particularly in analyzing MRI scans. As healthcare providers seek more accurate and reliable diagnostic methods, the demand for biopsy procedures is also increasing, driven by the need for definitive diagnosis to guide treatment. Moreover, optimism surrounding early detection capabilities is fueling market growth, especially for emerging methods that promise improved accuracy and reduced patient risk.

MRI (Dominant) vs. Biopsy (Emerging)

Magnetic Resonance Imaging (MRI) stands as the dominant diagnosis method in the Glioma Diagnosis Treatment Market, offering detailed imaging that is crucial for the assessment of various glioma types. It provides high-resolution images that allow for better tumor characterization and localization. On the other hand, biopsy is considered an emerging diagnosis method that is seeing rapid growth due to its ability to provide definitive and actionable information necessary for treatment decisions. This method is invaluable for confirming the presence of glioma and understanding its specific histological characteristics. While MRI is non-invasive and widely used in initial assessments, the rising demand for biopsy reflects the medical community's need for precision and certainty in glioma diagnostics, driving innovations in both fields.

By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

In the Glioma Diagnosis Treatment Market, the Treatment Type segment is primarily driven by surgery, which holds the largest market share due to its critical role in removing tumors and optimizing patient outcomes. Radiation therapy follows as a substantial contributor, often utilized post-surgery for effective tumor control. Chemotherapy, targeted therapy, and immunotherapy also play significant roles, with varying share distributions depending on the tumor grade and patient-specific factors.

Surgery: Dominant vs. Immunotherapy: Emerging

Surgery remains the dominant treatment modality in the Glioma Diagnosis Treatment Market due to its effectiveness in significantly reducing tumor mass and improving survival rates. It is considered the first-line treatment for most gliomas. Immunotherapy, conversely, is the emerging approach, gaining traction among clinicians for its potential to enhance the immune response against cancer cells. This innovative treatment includes therapies such as checkpoint inhibitors, offering new hopes, especially for patients who have recurred after conventional treatments. The effective blend of both treatment types signifies a pivotal shift in glioma management.

By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Glioma Diagnosis Treatment Market, the age group segment represents the largest demographic, with older adults predominantly affected by gliomas, accounting for a significant share of diagnoses. The distribution indicates that patients over the age of 50 form the bulk of cases, underscoring the need for targeted diagnostic and treatment options that cater to this population. Meanwhile, the gender segment is emerging as the fastest growing, driven by evolving research highlighting differences in glioma prevalence and outcomes between males and females. The growth trends within the patient demographics segment are propelled by increased awareness and early detection methods, which are leading to more accurate diagnosis rates, particularly among older adults. Advancement in genetic testing technologies is also playing a pivotal role in identifying at-risk populations. Gender considerations are gaining traction as a focus area for research, as understanding this aspect could significantly influence treatment protocols and patient outcomes, making gender a critical component of future glioma management strategies.

Age Group: 50+ (Dominant) vs. Gender: Female (Emerging)

The 50+ age group stands as the dominant demographic in the Glioma Diagnosis Treatment Market, as older individuals are more prone to developing gliomas, highlighting the critical need for age-specific treatment approaches. This group is often characterized by a higher likelihood of complex health conditions that require comprehensive treatment plans. In contrast, the female gender segment emerges as a focus of growing research interest. Studies indicate differences in incidence rates and treatment responses, with females exhibiting distinct biological characteristics. This emergence could significantly influence future treatment paradigms, emphasizing the importance of gender-responsive approaches in glioma diagnostics and therapies, aiming to enhance treatment efficacy and patient outcomes.

By Stage of Disease: High Grade (Largest) vs. Low Grade (Fastest-Growing)

In the Glioma Diagnosis Treatment Market, the distribution of market share among various stages of disease shows that high-grade gliomas hold the largest share, driven by their prevalence and complexity requiring advanced treatment solutions. In contrast, low-grade gliomas are emerging rapidly, showing increased recognition and treatment advancements, marking a significant shift in market dynamics. The growth trends are significantly influenced by a rising incidence of gliomas and improved diagnostic technologies that facilitate early detection. Additionally, the emphasis on personalized medicine and targeted therapies has a notable impact on low-grade and recurrent gliomas, making them the fastest-growing segment. Various new treatment options are being developed for these cases, contributing to the overall growth of this market segment.

High Grade (Dominant) vs. Low Grade (Emerging)

High-grade gliomas, such as glioblastoma, are characterized by their aggressive behavior and significant clinical challenges. These tumors often require intensive treatment strategies including surgery, radiation, and chemotherapy, making them a dominant segment within the glioma diagnosis and treatment market. The high fatality rate and complex treatment requirements keep high-grade gliomas as a focus for research and development in therapeutic options. In contrast, low-grade gliomas, while less aggressive, are emerging as a prominent area of interest due to advancements in diagnostic techniques and tailored treatment approaches. Their slower progression presents opportunities for prolonged management and optimized treatments, attracting attention from healthcare providers and researchers alike for potential innovations.

Get more detailed insights about Glioma Diagnosis Treatment Market
Request Free Sample

Regional Insights

North America : Leading Market Innovators

North America is poised to maintain its leadership in the Glioma Diagnosis Treatment Market, holding a significant market share of $1785.0M in 2024. The region benefits from advanced healthcare infrastructure, high R&D investments, and a growing prevalence of glioma cases. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, driving demand for effective treatment options. The increasing focus on personalized medicine further propels market growth, as patients seek tailored therapies that enhance outcomes. The competitive landscape in North America is robust, featuring key players such as Roche, Novartis, and Bristol-Myers Squibb. The U.S. stands out as the leading country, supported by a strong pipeline of new therapies and clinical trials. The presence of major pharmaceutical companies fosters innovation and collaboration, ensuring a steady influx of advanced treatment options. As the market evolves, partnerships between biotech firms and established players are expected to enhance the development of novel therapies, solidifying North America's position as a global leader.

Europe : Emerging Research and Development Hub

Europe is witnessing significant growth in the Glioma Diagnosis Treatment Market, with a market size of $1070.0M in 2024. The region benefits from a strong emphasis on research and development, supported by various government initiatives aimed at improving cancer care. Regulatory bodies like the European Medicines Agency (EMA) play a crucial role in facilitating the approval of new therapies, which is essential for meeting the rising demand for effective glioma treatments. The increasing incidence of glioma cases across Europe further drives market expansion, as healthcare systems adapt to provide better diagnostic and treatment options. Leading countries in this region include Germany, France, and the UK, where major pharmaceutical companies such as Merck and Bayer are actively involved in glioma research. The competitive landscape is characterized by a mix of established players and emerging biotech firms, fostering innovation. Collaborative efforts between academia and industry are enhancing the development of cutting-edge therapies, positioning Europe as a key player in The Glioma Diagnosis Treatment. The EMA states, "The development of innovative therapies is essential for improving patient outcomes in glioma treatment," highlighting the region's commitment to advancing cancer care.

Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is emerging as a significant player in the Glioma Diagnosis Treatment Market, with a market size of $550.0M in 2024. Factors such as increasing healthcare expenditure, rising awareness about glioma, and improving access to advanced medical technologies are driving market growth. Governments in countries like China and India are investing heavily in healthcare infrastructure, which is crucial for enhancing diagnostic and treatment capabilities. The growing prevalence of glioma cases in this region necessitates the development of effective treatment options, further fueling market demand. Key countries in the Asia-Pacific region include China, Japan, and Australia, where local and international pharmaceutical companies are actively engaged in glioma research. The competitive landscape is evolving, with a mix of established firms and startups focusing on innovative therapies. Collaborations between research institutions and industry players are expected to accelerate the development of new treatment modalities, positioning the Asia-Pacific region as a promising market for glioma diagnosis and treatment. The region's potential is underscored by its commitment to improving cancer care and patient outcomes.

Middle East and Africa : Emerging Healthcare Initiatives

The Middle East and Africa (MEA) region is gradually developing its Glioma Diagnosis Treatment Market, with a market size of $171.87M in 2024. The growth is driven by increasing healthcare investments and initiatives aimed at improving cancer care. Governments are focusing on enhancing healthcare infrastructure and access to advanced treatment options, which is crucial for addressing the rising incidence of glioma. The region's diverse healthcare landscape presents both challenges and opportunities for market players, as they navigate varying regulatory environments and healthcare needs. Leading countries in the MEA region include South Africa and the UAE, where there is a growing presence of both local and international pharmaceutical companies. The competitive landscape is characterized by a mix of established players and emerging firms, all striving to improve treatment accessibility. Collaborative efforts between governments and healthcare providers are essential for advancing glioma treatment options, ensuring that patients receive timely and effective care. The region's commitment to enhancing cancer care is evident in its ongoing healthcare initiatives and partnerships.

Glioma Diagnosis Treatment Market Regional Image

Key Players and Competitive Insights

The Glioma Diagnosis Treatment Market is characterized by a dynamic competitive landscape, driven by advancements in diagnostic technologies and therapeutic innovations. Key players such as Roche (CH), Novartis (CH), and Merck (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche (CH) focuses on precision medicine, leveraging its expertise in molecular diagnostics to develop targeted therapies. Meanwhile, Novartis (CH) emphasizes strategic partnerships and collaborations to expand its research capabilities, particularly in immunotherapy. Merck (DE) is investing heavily in digital transformation, aiming to streamline operations and improve patient outcomes through data analytics and AI integration. Collectively, these strategies contribute to a competitive environment that is increasingly centered on innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like AstraZeneca (GB) and Pfizer (US) is notable, as they leverage their extensive resources and The Glioma Diagnosis Treatment dynamics. This competitive structure fosters an environment where innovation is paramount, and companies are compelled to differentiate themselves through unique offerings and strategic initiatives.

In November Roche (CH) announced a groundbreaking partnership with a leading biotech firm to develop a novel biomarker for glioma diagnosis. This collaboration is expected to enhance the accuracy of early detection, potentially revolutionizing treatment pathways. The strategic importance of this move lies in Roche's commitment to precision medicine, which aligns with current trends towards personalized healthcare solutions. By integrating advanced diagnostics with therapeutic strategies, Roche positions itself as a leader in the evolving landscape of glioma treatment.

In October Novartis (CH) launched a new clinical trial focused on a combination therapy for glioblastoma, a particularly aggressive form of glioma. This initiative underscores Novartis's dedication to advancing treatment options through innovative research. The trial's outcomes could significantly impact treatment protocols, enhancing the company's reputation as a pioneer in oncology. Such strategic actions not only bolster Novartis's portfolio but also reflect a broader industry trend towards developing multifaceted treatment approaches.

In September Merck (DE) unveiled a new AI-driven platform designed to optimize patient management in glioma treatment. This platform aims to enhance treatment personalization by analyzing patient data to predict responses to various therapies. The strategic significance of this development lies in Merck's focus on integrating technology into healthcare, which is increasingly becoming a competitive differentiator. As digital solutions gain traction, Merck's initiative positions it favorably in a market that values innovation and efficiency.

As of December current competitive trends in the Glioma Diagnosis Treatment Market are heavily influenced by digitalization, sustainability, and AI integration. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements and supply chain reliability. This shift suggests that companies that prioritize innovation and adaptability will be better positioned to thrive in an increasingly complex market.

Key Companies in the Glioma Diagnosis Treatment Market include

Industry Developments

April 2021 In order to treat glioblastoma multiforme, Lineage Cell Therapeutics and Immunomic Therapeutics engaged into a licencing agreement for the development of the allogeneic VAC cancer immunotherapy platform.

Future Outlook

Glioma Diagnosis Treatment Market Future Outlook

The Glioma Diagnosis Treatment Market is projected to grow at a 5.2% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies and increasing prevalence of gliomas.

New opportunities lie in:

  • Development of AI-driven diagnostic tools for early detection.
  • Expansion of telemedicine platforms for remote consultations.
  • Investment in personalized treatment plans based on genetic profiling.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment methodologies and patient outcomes.

Market Segmentation

Glioma Diagnosis Treatment Market Treatment Type Outlook

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

Glioma Diagnosis Treatment Market Diagnosis Method Outlook

  • Magnetic Resonance Imaging
  • Computed Tomography
  • Biopsy
  • Positron Emission Tomography
  • Electroencephalography

Glioma Diagnosis Treatment Market Stage of Disease Outlook

  • Early Stage
  • Intermediate Stage
  • Advanced Stage
  • Recurrent Stage

Glioma Diagnosis Treatment Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Genetic Profile
  • Health Status
  • Socioeconomic Status

Report Scope

MARKET SIZE 2024 3576.87(USD Million)
MARKET SIZE 2025 3762.94(USD Million)
MARKET SIZE 2035 6248.39(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.2% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Roche (CH), Novartis (CH), Merck (DE), Bristol-Myers Squibb (US), Eli Lilly (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE)
Segments Covered Diagnosis Method, Treatment Type, Patient Demographics, Stage of Disease
Key Market Opportunities Advancements in precision medicine enhance treatment efficacy in the Glioma Diagnosis Treatment Market.
Key Market Dynamics Technological advancements in imaging and treatment modalities are reshaping the Glioma Diagnosis Treatment landscape.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current market valuation of the Glioma Diagnosis Treatment Market?

The Glioma Diagnosis Treatment Market was valued at approximately 3576.87 USD Million in 2024.

What is the projected market size for the Glioma Diagnosis Treatment Market by 2035?

The market is expected to reach around 6248.39 USD Million by 2035.

What is the expected CAGR for the Glioma Diagnosis Treatment Market during the forecast period?

The market is projected to grow at a CAGR of 5.2% from 2025 to 2035.

Which companies are the key players in the Glioma Diagnosis Treatment Market?

Key players include Roche, Novartis, Merck, Bristol-Myers Squibb, Eli Lilly, Amgen, AstraZeneca, Pfizer, and Bayer.

What are the primary diagnosis methods used in the Glioma Diagnosis Treatment Market?

Primary diagnosis methods include Magnetic Resonance Imaging, Computed Tomography, Biopsy, Positron Emission Tomography, and Electroencephalography.

How much revenue did Magnetic Resonance Imaging generate in 2024?

Magnetic Resonance Imaging generated approximately 1075.0 USD Million in 2024.

What treatment types are prevalent in the Glioma Diagnosis Treatment Market?

Prevalent treatment types include Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy.

What was the revenue generated by Surgery in 2024?

Surgery generated around 1075.0 USD Million in 2024.

How does patient demographics influence the Glioma Diagnosis Treatment Market?

Patient demographics, including age group, gender, genetic predisposition, socioeconomic status, and geographic location, significantly impact market dynamics.

What was the revenue for high-grade gliomas in 2024?

High-grade gliomas accounted for approximately 1200.0 USD Million in 2024.
Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed oncology and neurosurgery journals, clinical trial registries, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, World Health Organization (WHO) International Agency for Research on Cancer (IARC) Global Cancer Observatory, Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries, National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI/PubMed), American Society of Clinical Oncology (ASCO), Society for Neuro-Oncology (SNO), European Association of Neuro-Oncology (EANO), American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), ClinicalTrials.gov registry database, World Cancer Research Fund (WCRF) International, Organisation for Economic Co-operation and Development (OECD) Health Statistics, EU Eurostat Healthcare Database, National Health Service (NHS) England Cancer Statistics, Central Brain Tumor Registry of the United States (CBTRUS), GLOBOCAN cancer incidence database, and national cancer registry reports from key markets (UK Office for National Statistics, German Federal Statistical Office, Japan Ministry of Health Labour and Welfare, China National Cancer Center). These sources were used to collect glioma incidence and prevalence statistics, regulatory approval data for temozolomide, bevacizumab, lomustine, and other therapeutic agents, clinical safety and efficacy studies, molecular diagnostic trends (IDH mutation testing, MGMT methylation analysis), and market landscape analysis for diagnostic imaging modalities (MRI, PET, advanced CT), surgical navigation systems, radiation therapy devices, and emerging immunotherapy platforms.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources encompassed Chief Executive Officers, Chief Medical Officers, VPs of Oncology R&D, regulatory affairs heads, and commercial directors from pharmaceutical manufacturers (Roche, Novartis, Merck, Bristol-Myers Squibb), diagnostic imaging equipment manufacturers (Siemens Healthineers, GE Healthcare, Philips), radiation therapy system providers (Varian Medical Systems, Elekta), molecular diagnostics companies, and contract research organizations (CROs) conducting neuro-oncology trials. Board-certified neuro-oncologists, neurosurgeons, radiation oncologists, neuroradiologists, medical directors of comprehensive cancer centers, procurement leads from academic medical centers, hospital pharmacy directors, and healthcare payers specializing in oncology reimbursement comprised demand-side sources. Primary research has confirmed the product pipeline timelines for CAR-T cell therapies, tumor-treating fields (Optune), and next-generation imaging agents. It has also gathered insights on clinical adoption patterns of 5-ALA fluorescence-guided surgery, proton therapy expansion, precision medicine protocols, pricing strategies for branded vs. generic temozolomide, and reimbursement dynamics for bevacizumab in recurrent glioblastoma. The market segmentation has been validated across glioma types (primary vs. secondary), diagnostic modalities (MRI, PET, molecular testing), treatment categories (surgery, chemotherapy, radiation, immunotherapy, targeted therapy), and end-user settings (hospitals, diagnostic centers, research institutions).

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through revenue mapping, procedure volume analysis, and treatment cost modeling. The methodology included:

Identification of 55+ key manufacturers and service providers across North America, Europe, Asia-Pacific, and Latin America, encompassing pharmaceutical companies (Roche, Novartis, Merck, BMS, Eli Lilly, Amgen, AstraZeneca, Pfizer, Bayer), diagnostic imaging equipment manufacturers (Siemens Healthineers, GE Healthcare, Canon Medical Systems, Hitachi), radiation therapy providers (Varian, Elekta, Brainlab), and molecular diagnostics firms (Agilent Technologies, Thermo Fisher Scientific, Illumina)

Product mapping across diagnostic categories (MRI systems, PET scanners, CT scanners, EEG equipment, molecular testing platforms, biopsy devices) and treatment categories (surgical equipment, chemotherapeutic agents, radiation therapy systems, immunotherapy products, targeted therapy drugs)

Analysis of reported and modeled annual revenues specific to glioma-related portfolios, including temozolomide sales, bevacizumab neuro-oncology indications, tumor-treating fields devices, and advanced imaging contrast agents

Coverage of manufacturers representing 72-78% of global market share in 2024

Extrapolation using bottom-up (glioma incidence rates × treatment penetration × average selling price by country/region) and top-down (manufacturer revenue validation, hospital procurement data triangulation) approaches to derive segment-specific valuations for low-grade glioma, high-grade glioma, and recurrent glioblastoma subsegments

This methodology ensures comprehensive coverage of the glioma diagnosis and treatment ecosystem while maintaining the rigorous standards of market research with verifiable, authoritative sources.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓